Women see more adverse events with chemotherapy, and newer cancer treatments, study finds
Research has long shown that women are more likely than men to have severe reactions to chemotherapy treatments. Women also experience greater toxicity with targeted therapies and immunotherapies.
Overall, women were 34% more likely than men to experience severe adverse effects in response to their cancer treatments.
This figure increased to 49% for women receiving immunotherapies, according to a recent study in the Journal of Clinical Oncology (JCO).